LBA
Letko, Brosseau & Associates Portfolio holdings
AUM
$5.23B
This Quarter Return
+10.36%
1 Year Return
+15.79%
3 Year Return
+49.62%
5 Year Return
+161.51%
10 Year Return
+219.13%
AUM
$5.23B
AUM Growth
+$5.23B
(+11%)
Cap. Flow
+$95.9M
Cap. Flow
% of AUM
1.83%
Top 10 Holdings %
Top 10 Hldgs %
36.97%
Holding
98
New
9
Increased
41
Reduced
32
Closed
5
Top Buys
| 1 |
Adient
ADNT
|
$28.8M |
| 2 |
Rogers Communications
RCI
|
$25.7M |
| 3 |
Open Text
OTEX
|
$23M |
| 4 |
Alphabet (Google) Class C
GOOG
|
$18.9M |
| 5 |
AMRZ
Amrize Ltd
AMRZ
|
$13.6M |
Top Sells
| 1 |
Skechers
SKX
|
$40.9M |
| 2 |
Toronto Dominion Bank
TD
|
$5.65M |
| 3 |
Hudbay
HBM
|
$3.5M |
| 4 |
Nutrien
NTR
|
$3.41M |
| 5 |
Citigroup
C
|
$2.88M |
Sector Composition
| 1 | Financials | 34.05% |
| 2 | Communication Services | 19.07% |
| 3 | Materials | 11.57% |
| 4 | Healthcare | 9.74% |
| 5 | Technology | 7.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
ARS Pharmaceuticals
SPRY
$1.08B
| $431K | 0.01% |
24,700
| – | – |
|
|
77
Skechers
SKX
$9.5B
| $424K | 0.01% |
6,725
-648,075
| -99% | -$40.9M |
|
78
Fortis
FTS
$24.9B
| $405K | 0.01% |
8,500
| – | – |
|
|
EMA
79
Emera Incorporated
EMA
$14.1B
| $388K | 0.01% |
+8,485
| New | +$388K |
|
80
NXP Semiconductors
NXPI
$57.5B
| $388K | 0.01% |
+1,775
| New | +$388K |
|
81
Vale
VALE
$43.6B
| $356K | 0.01% |
36,650
| – | – |
|
82
Microsoft
MSFT
$3.76T
| $317K | 0.01% |
638
| – | – |
|
83
Freeport-McMoran
FCX
$66.3B
| $300K | 0.01% |
+6,925
| New | +$300K |
|
84
MeiraGTx Holdings
MGTX
$590M
| $295K | 0.01% |
45,300
| – | – |
|
85
Ero Copper
ERO
$1.54B
| $244K | ﹤0.01% |
14,500
| – | – |
|
86
Mineralys Therapeutics
MLYS
$1.94B
| $223K | ﹤0.01% |
16,500
| – | – |
|
87
NewAmsterdam Pharma
NAMS
$2.8B
| $213K | ﹤0.01% |
+11,775
| New | +$213K |
|
88
TScan Therapeutics
TCRX
$106M
| $139K | ﹤0.01% |
95,875
+18,775
| +24% | +$27.2K |
|
89
Aura Biosciences
AURA
$394M
| $133K | ﹤0.01% |
21,200
| – | – |
|
90
89bio
ETNB
$1.37B
| $105K | ﹤0.01% |
10,700
| – | – |
|
91
Replimune Group
REPL
$460M
| $100K | ﹤0.01% |
+10,800
| New | +$100K |
|
92
Humacyte
HUMA
$231M
| $96K | ﹤0.01% |
45,950
+21,150
| +85% | +$44.2K |
|
93
Aldeyra Therapeutics
ALDX
$350M
| $66.3K | ﹤0.01% |
17,300
| – | – |
|
94
Duke Energy
DUK
$94.5B
| – | – |
-2,050
| Closed | -$250K |
|
|
IIF
95
Morgan Stanley India Investment Fund
IIF
$253M
| – | – |
-113,375
| Closed | -$2.77M |
|
96
Kimberly-Clark
KMB
$42.5B
| – | – |
-1,515
| Closed | -$215K |
|
97
Pliant Therapeutics
PLRX
$105M
| – | – |
-10,400
| Closed | -$14K |
|
98
ProKidney
PROK
$319M
| – | – |
-15,900
| Closed | -$13.9K |
|